Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy

Human Reproduction

Volumn 22, Issue 6, 2007, Pages 1769-1777

  Tannen, Richard L ^a   Weiner, Mark G ^a   Xie, Dawei ^a   Barnhart, Kurt ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Obstetrics and Gynecology ^*

Author keywords

Cohort studies; Coronary heart disease; Hormone replacement therapy; Hysterectomy; Menopause

Indexed keywords

CONJUGATED ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COLON CANCER; FEMALE; HAZARD RATIO; HEART INFARCTION; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MONOTHERAPY; POSTMENOPAUSE; UTERUS; WOMEN'S HEALTH;

EQUIDAE;

EID: 34447331424     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dem031     Document Type: Article

References (32)

1. Bladbjerg EM, Skouby SO, Andersen LF and Jespersen J (2002) Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Human Reprod 17,3235-3241.
2. Brett KM (2005) Can hysterectomy be considered a risk factor for cardiovascular disease? Circulation 111,1456-1458.
3. D'Agostino RB and Rubin DB (2000) Estimating and using propensity scores with partially missing data. J Am Stat Assoc 95,749-759.
4. Falkeborn M, Schairer C, Naessen T and Persson I (2000) Risk of myocardial infarction after oophorectomy and hysterectomy. J Clin Epidemiol 53,832-837.
5. Fournier A, Berrino F, Riboli E, Avenel V and Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3 N-EPIC cohort. Int J Cancer 114,448-454.
6. Gelfand JM, Margolis DJ and Dattani H (2005) The UK General Practice Research Data Base. In Strom BL (ed.) Pharmacoepidemiology. 4th edn. John Wiley and Sons, New York, USA, pp. 337-346.
7. Howard BV, Kuller L, Langer R, Manson JE, Allen C, Assaf A, Cochrane BB, Larson JC, Lasser N, Rainford M et al. (2005) Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy. The Women's Health Initiative Observational Study. Circulation 111,1462-1470.
8. Hsia J, Barad D, Margolis K, Rodabough R, Mcgovern PG, Limacher MC, Oberman A and Smoller S (2003) Usefulness of prior hysterectomy as an independent predictor of Framingham risk score (the women's health initiative) Am J Cardiol 92,264-269.
9. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S et al. (2006) Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative. Arch Intern Med 166,357-365.
10. Kim CJ, Min YK, Ryu WS, Kwak JW and Ryoo UH (1996) Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Arch Intern Med 156,1693-700.
11. Li CI, Malone KE, Porter PI, Weiss NS, Tang MC, Cushing-Haugen KL and Daling JR (2003) Relationships between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289,3254-3263.
12. Lyytinen H, Pukkala E and Ylikorkala O (2006) Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 108,1354-1360.
13. Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362,419-427.
14. Nozaki M, Hideaki N, Koera K, Shimokawa H and Nakano H (2004) Total abdominal hysterectomy may be a risk factor for acute myocardial infarction in postmenopausal women: An age matched, case-controlled retrospective analysis. J Gynecol Surg 20,75-80.
15. Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, et al. (2006) Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 163,589-599.
16. Raghunathan TE, Solenberger PW and Van Hoewyk J (1998) IVEware: Imputation and Variance Estimation Software. Institute for Social Research, University of Michigan, Ann Arbor, MI, USA.
17. Raghunathan TE, Lepkowski JM, Van Hoewyk J and Solenberger PW (2001) A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 27,85-95.
18. Register TC, Adams MR, Golden DL and Clarkson TB (1998) Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vas Biol 18,1164-1171.
19. Rosenberg I, Hennekens CH, Rosner B, Belanger C, Rothman KJ and Speizer FE (1981) Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 139,47-51.
20. Rosenbaum P and Rubin D (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70,41-55.
21. Rosenbaum P and Rubin D (1984) Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79,516-524.
22. Ross RK, Paganini-Hill A, Wan PC and Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk. estrogen versus estrogen plus progestin. J Natl Cancer Inst 92,328-332.
23. Rubin D (1987) Multiple Imputation for Non-response in Surveys. John Wiley and Sons, Inc, New York, NY, USA.
24. Schairer C, Lubin J, Troisi R, Stergeon S, Brinton L and Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283,485-491.
25. Smith NL, Heckbert SR, Lemaitre R, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR and Psaty BM (2004) Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292,1581-1587.
26. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH and Johnson SR (2003) The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 13(9 suppl), S78-S86.
27. Tannen RL, Weiner MG and Marcus SM (2006) Simulation of the Syst-Eur randomized control trial using a primary care electronic medical record was feasible. J Clin Epidemiol 59,254-264.
28. Tannen RL, Weiner MG, Xie D and Barnhart K (2007) A simulation using data from a primary care practice database closely replicated the Women's Health Initiative Trial. J Clin Epidemiol, in press.
29. The Women's Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 291,1701-1712.
30. Weiner MG, Barnhart K, Xie D and Tannen RL. Hormone replacement therapy and coronary heart disease in young women. (submitted for publication).
31. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288,321-333.
32. Yager JD and Davidson NE (2006) Estrogen carcinogenesis in breast cancer. New Engl J Med 354,270-282.